Amerikanische Gesellschaft für Hirudotherapie

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Research article published in Journal of thrombosis and thrombolysis (2005)

Zuletzt aktualisiert: 18. Juni 2026Geprüft von: ASH Editorial Board
Forschungsartikel – EvidenzreviewArtikelreferenz
Evidence: Research reportKlinische StudienJaffer et al. · Journal of thrombosis and thrombolysis, 2005

Abstract

BACKGROUND: Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism. Suspension of warfarin therapy is often required to prepare patients for invasive procedures or surgeries. To protect these patients against thromboembolism while they are off warfarin, shorter-acting parenteral agents such as low-molecular-weight heparins (LMWHs) are often used. We conducted a retrospective observational study of our anticoagulation clinic patients to assess the safety and efficacy of LMWHs using a standardized protocol for periprocedural anticoagulation therapy. METHODS: We included 69 consecutive patients who required interruption of their long-term warfarin therapy between August 2001 and August 2002, and were deemed by the treating physician to be at high enough risk for perioperative thromboembolism to justify bridging anticoagulation. We used a standard bridging therapy protocol in our anticoagulation clinic. Sixty-six patients received enoxaparin and three patients received tinzaparin for a mean duration of 7.7 days postoperatively. Outcomes were assessed for 30 days post-procedure. Safety outcomes included major bleeding and minor bleeding. Efficacy outcomes included thromboembolic event or death. RESULTS: There were two major bleeding events, one minor bleeding event, and no cases of thromboembolism. Twelve patients experienced some bruising around the injection site. CONCLUSIONS: LMWH administration using our standard outpatient bridging protocol for perioperative anticoagulation appears to be relatively safe and efficacious, offering an alternative to inpatient administration of intravenous unfractionated heparin (UFH). Our study provides additional evidence to the limited published observational data regarding the safety and efficacy of LMWH as bridging therapy in the perioperative and periprocedural setting. Large, multicenter, randomized controlled trials are necessary to fully assess the safety and efficacy of LMWH for perioperative anticoagulation.We conducted a retrospective observational study of 69 consecutive anticoagulation clinic patients on warfarin between August 2001 and August 2002, who were undergoing a procedure or surgery. The study was done to assess the safety and efficacy of an outpatient LMWH bridging protocol. Sixty-six patients received enoxaparin and three patients received tinzaparin for a mean duration of 3 days preoperatively and 7.7 days postoperatively. Outcomes were assessed for 30 days post-procedure. Safety outcomes included major bleeding and minor bleeding. Efficacy outcomes included thromboembolic event or death. There were two major bleeding events, one minor bleeding event, and no cases of thromboembolism. Twelve patients experienced some bruising around the injection site.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAgedAged, 80 and overAnticoagulantsAtrial FibrillationEnoxaparinFemaleHeart Valve ProsthesisHemorrhageHeparin, Low-Molecular-WeightHumansMale

Zusammenfassung

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Warum dies für die Hirudotherapie relevant ist

Diese retrospektive Beobachtungsstudie bewertete die Sicherheit und Wirksamkeit eines standardisierten ambulanten LMWH-Bridging-Protokolls bei 69 konsekutiven Patienten einer Antikoagulationsambulanz unter Langzeit-Warfarin-Therapie, die eine periprozedurale Antikoagulation benötigten, wobei 66 Patienten Enoxaparin und 3 Patienten Tinzaparin für durchschnittlich 3 Tage präoperativ und 7,7 Tage postoperativ erhielten. Die Ergebnisse über 30 Tage zeigten zwei schwere Blutungskomplikationen, eine geringfügige Blutungskomplikation, keine Thromboembolie sowie Injektionsstellen-Hämatome bei 12 Patienten. Für den Bereich der ASH behandelt dieser Artikel ausschließlich das Management einer konventionellen Heparin-basierten Antikoagulation und enthält keinerlei Inhalte zu Egeln, Hirudin oder dem Egel-Sekretom. Die Relevanz für die Hirudotherapie ist gleich null – es handelt sich um eine klinisch-pharmakologische Studie zum LMWH-Bridging ohne vertretbare Verbindung zur Egeltherapie oder zu aus Egeln gewonnenen Verbindungen.

Zitation

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Jaffer et al. · Journal of thrombosis and thrombolysis, 2005

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Freigabe für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.